FDA-approved Nerivio REN wearable device is a noninvasive, drug-free way to treat migraine headaches
Nerivio, an FDA approved and REN wearable device, is a drug free way to treat migraine headaches
Nerivio, an FDA approved and REN wearable device, is a drug free way to treat migraine headaches
A device that is a noninvasive, drug-free way to treat and prevent migraine headaches is now FDA-approved for use in children.
Millions of people suffer from migraine headaches that can be debilitating. Treatments range from drugs to botox injections. But for many, nothing works.
Doctors said this device, Nerivio REN wearable, could change that.
Alison Kerber said it's a device that's turned her life around, helping control her migraine headaches.
"Dealing with chronic pain on a daily basis was really difficult, and I was often sidelined," she said.
The Downingtown working mom said traditional migraine medications caused serious side effects, so she turned to the Nerivio REN wearable device that sticks to the skin.
"It works by sending an electrical impulse via the nerve fibers in the upper arm up to the brain to get your brain to activate its own pain-relieving capabilities," said Dr. Heidi Kling-Newnam, a Penn Medicine nurse practitioner.
Kling-Newnam, who works with migraine patients, said the stimulation tricks the brain into relieving migraine pain.
"If you can mimic something that's like pain, that your body perceives as pain, even though this device isn't painful.... it can trigger the release of these natural chemicals that your body makes to relieve pain, almost like natural pain relievers," said Kling-Newnam.
Kerber, who's been using the device for about a year, said she controls the level of stimulation from her phone.
"I'm starting to feel the stimulation right now in my arm. I continue to increase that until it no longer feels comfortable," she said. "And then I dial it back just a little bit."
The device is used for 45 minutes either as a treatment during a migraine or every other day to prevent them.
"I think it's a really great drug-free, noninvasive option," said Kerber.
Some insurance companies don't cover the prescription device that can cost about $90 a month.
Kerber said for her, it's worth the price to be pain-free.
Doctors said the device doesn't work for everyone, but there are no serious side effects. And it's often used in conjunction with other treatments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
8 minutes ago
- Associated Press
How nonprofits are teaming up to fight hunger in South Dakota
Forty South Dakota organizations have formed a collaborative to help people who don't have enough to eat at a time of reduced government support and increased demand. A 'meeting place' is how Jennifer Folliard characterizes the South Dakota Healthy Nutrition Collaborative. She's a steering committee member and coordinator for the SDHNC, which launched in September. It's the first organization of its kind in the state dedicated to helping the 113,500 South Dakotans who were food insecure in 2023, meaning they had limited or inconsistent access to enough food, according to the most recent data from Feeding America. The goal is to improve their health through education, sharing resources and aligning actions across the state, Folliard said. 'We've sort of been a place to come together and try to figure out solutions as the crises hit,' she said. 'We are people coming together that want to make systems change and want to do better on programming,' Folliard added. 'So it's a space for people to come together to say, 'Hey, these are our priorities. We are a bunch of organizations throughout the state. We recognize food insecurity's an issue, and how do we make changes that are going to be systemic?'' Food programs expanding statewide Feeding South Dakota is one of the SDHNC partners and plays a big role because it's the state's largest food relief network. The nonprofit operates out of three distribution centers in Rapid City, Pierre and Sioux Falls. Through its programs and partnerships, it distributes food to pantries in all 66 counties, said Feeding South Dakota representative Stacey Andernacht. In the 2024 fiscal year, Feeding South Dakota distributed 11.7 million meals and served 12,772 families through its 263 community partners, according to data from its website. Feeding South Dakota asked the South Dakota Legislature for $3 million on July 23 to help fill the gap made from the U.S. Department of Agriculture cancelling 1.5 million pounds of food normally allocated to Feeding South Dakota. Bread Break is another member of the collaborative. It is a growing Sioux Falls nonprofit that collects usable, extra food from restaurants, gas stations, grocery stores and other businesses and delivers it to more than 30 receiving partners like food banks and churches. Executive director Pam Cole said she's seen an increase in people using community solutions during the past few years, and recently, the need has increased more rapidly. 'The rate is definitely increasing exponentially at this point. It was already hard for people, and now it's just untenable for people,' Cole said. 'I don't know how they're making it through the day, and it's getting to a critical point.' Last year, Bread Break recovered more than 300,000 pounds of food and is on track to recover at least 400,000 pounds this year, Cole said. Bread Break's goal is to help the growing need by expanding out from Sioux Falls to other towns throughout the state. Cole is in talks with people in Rapid City to try and get the program started there. 'We are exclusively in Sioux Falls right now, but we have a lot of interest in taking our model to other cities,' Cole said. 'I've had at least three different people reach out to me in the last two months about Rapid City needing something like this.' According to the United States Environmental Protection Agency, 40% of food in the U.S. is lost or wasted annually. That equates to around $218 billion, or 1.3% of the country's gross domestic product. 'I fully believe that our food system in the United States is broken and needs great repair. We should be studying this at the federal level. We should be making a concerted effort to really look at what's going wrong,' Cole said. 'That is an enormous amount of waste. Yes, I know it's a drop in the bucket. But if we can't take care of this, I'm not sure what we really can take care of.' The insecure state of food insecurity Sioux Falls resident Traci Praul uses community solutions to combat her own food insecurity. She relies on Supplemental Nutrition Assistance Program (SNAP) benefits, formerly called food stamps, and attends Church on the Street, which also provides food and laundry services. When she first moved back to Sioux Falls from Arizona, she lived at the Union Gospel Mission homeless shelter. Praul feels covered by her SNAP benefits. However, she said rising costs of food because of inflation in recent years have made it harder on everyone. 'It's not knowing from one moment to the next what DSS (the Department of Social Services) or the federal government is going to do,' Praul said. 'I've heard a lot of people complaining, 'Wait a minute, we need this (SNAP), 'cause we're living paycheck to paycheck.'' Folliard said that despite the uncertainty of federal and state government funding, organization leaders who try to ease the food insecurity problem continue to push for solutions. 'I didn't grow up in South Dakota, but I have lived here for eight years now, and people in South Dakota are very resourceful,' she said. 'I've seen this level of resilience that's pretty inspiring.' ___ This story was originally published by South Dakota News Watch and distributed through a partnership with The Associated Press.
Business Upturn
12 minutes ago
- Business Upturn
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
By GlobeNewswire Published on August 4, 2025, 23:31 IST PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to FDA and to be conducted by Immuthera has been received favorably, may include Polish patients in the U.S. Statistical analysis, and could be treated as pivotal. The project has received an $11.3 million non-dilutive grant from the Polish Medical Research Agency. PolTREG is developing Multi-edited, Allogeneic CAR-Tregulatory cell therapies which can be used to treat patients diagnosed with T1D (Stage 3), which, in combination with PTG-007 in Stage 1 and Stage 2, will provide clinical solutions for patients across all Stages of T1D. 4 August 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a pioneer in cell therapies for autoimmune diseases, and its U.S. subsidiary Immuthera, announced that they have administered the first dose of PTG-007 to a patient in their Phase II clinical trial for pre-symptomatic type 1 diabetes. The trial, called 'Pre-Treg' will enroll up to 150 genetically high-risk children and adolescents (aged 3–18) who have not yet developed clinical symptoms of the disease. If successful, PolTREG aims to develop and register the world's first therapy to prevent the onset of type 1 diabetes symptoms. The company has proposed a parallel study to Pre-Treg to the U.S. Food and Drug Administration (FDA) in a recent Pre-IND meeting. The FDA's response was that the U.S. Trial could potentially be registrational. Further, patients enrolled in Poland at Stage 1 of the disease may, upon completion of enrollment, be included in the U.S. statistical analysis of the study. 'Long-term data from our clinical program of PTG-007 in symptomatic type 1 diabetes confirm both the safety and efficacy of the therapy. Modern medicine is increasingly focusing on interventions applied earlier or even before the first clinical symptoms appear. Our therapy fits perfectly into this paradigm. By administering it at the earliest stage of disease development, we anticipate highly promising outcomes—possibly even halting disease progression before clinical symptoms emerge. If the trial confirms the therapy's efficacy, we have the opportunity to develop and register the world's first drug to prevent the clinical onset of type 1 diabetes. We believe this therapy holds significant market and partnership potential' – said Prof. Piotr Trzonkowski, CEO and Co-Founder of PolTREG S.A. The Phase II study will include 150 participants in a randomized, placebo-controlled design. Recruitment is ongoing at three academic centers in Poland, with six additional clinical hospitals set to begin enrollment shortly. PolTREG has been awarded a non-dilutive grant of PLN 31.7 million (approx. $11.3 million) from the Polish Medical Research Agency to support the execution of this Phase II trial. PreTreg is one of PolTREG's flagship programs. In type 1 diabetes, the autoimmune destruction of insulin-producing pancreatic islets underscores the importance of early intervention. In the pre-symptomatic phase, a sufficient number of islets remain to maintain normal glucose regulation, and the autoimmune process is still limited and more readily controllable. Preventive therapy at this stage could halt the autoimmune attack, leaving patients genetically predisposed but clinically healthy for life. Upon successful completion of this trial and confirmation of safety and efficacy, PolTREG could establish the first approved drug to prevent symptomatic type 1 diabetes. Type 1 diabetes progresses through three stages. Stages 1 and 2 is considered presymptomatic and occurs in young children, typically 3 years old or older. Because these patients are not yet sick, safety is the highest priority. PTG-007's 12 year safety data makes it an ideal treatment for this age group and this stage of disease. Diagnosis of Type 1 Diabetes occurs in Stage 3 when symptoms occur which can lead to potentially life threatening complications such as diabetic ketoacidocis, heart and blood vessel disease, nerve damage, eye damage, kidney disease, and foot damage. These patients are typically older and require supplemental insulin. Due to the complications in Stage 3, more aggressive treatments are warranted. PolTREG and Immuthera are developing Tregulatory cell therapies that have clinically derived edits to improve function, modifications to make them 'off-the-shelf' (allogeneic), and a Chimeric Antigen Receptor to improve targeting of the disease causing cells that drive the autoimmune response. Taken together, PolTREG and Immuthera have a pipeline of Tregulatory cell therapies that will cover the full spectrum of presymptomatic and symptomatic Type 1 Diabetes. PolTREG is also expanding its U.S. presence. In mid-June, the company established its wholly owned U.S. subsidiary, Immuthera, registered as a Delaware C Corporation. In recent weeks, prominent experts in diabetes and neuroimmunology—Prof. Jay Skyler, Prof. Desmond Schatz, and Prof. Lawrence Steinman—joined the company's Scientific Advisory Board. In late July, PolTREG received the formal outcome of its pre-IND meeting with the FDA and is now preparing its IND submission. The company has partnered with Noble Capital Markets, Inc. and Kinexum Services LLC to support its U.S. regulatory strategy, and is collaborating with Swiss-based Antion Biosciences to develop next-generation allogeneic Treg therapies. About PolTREG: PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera: Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities and asset pipeline along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For further information please contact: PolTREG Piotr TrzonkowskiChief Executive Officer [email protected] +48 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
36 minutes ago
- Yahoo
RPMG Welcomes Dr. James Weinberger and Launches Center for Male Fertility
LOS ANGELES, August 04, 2025--(BUSINESS WIRE)--Reproductive Partners Medical Group (RPMG), trusted leader in advanced fertility care and member of the Ivy Fertility network, is proud to announce the September 2025 launch of its new Center for Male Fertility, led by fellowship-trained reproductive urologist Dr. James Weinberger. As the Center's Director, Dr. Weinberger brings deep expertise in male reproductive health and a commitment to providing men with the same high level of care and clarity that RPMG is known for. "Fertility is a shared journey, and male fertility deserves just as much care and attention," said Dr. Weinberger. "Our goal is to offer answers and options in a space that's supportive, cutting-edge and designed specifically for men." Built to meet a growing need in reproductive medicine, the Center for Male Fertility provides men with a dedicated, compassionate space to understand and optimize their reproductive health. Services will include semen analysis, hormone evaluation and optimization, microsurgical sperm retrieval (mTESE), varicocelectomy, vasectomy reversal, and consultative support for couples undergoing IVF or ICSI. As one of just 2% of urologists in the U.S. fellowship-trained in male infertility microsurgery, Dr. Weinberger brings a level of precision and expertise that directly impacts outcomes. His advanced training ensures that men at RPMG receive care that goes beyond the standard. "Men are ready to be part of the fertility conversation. They just need a place to start," said Christina Westbrook, COO/CNO of RPMG. "This Center is about access and shifting how we support the full family-building journey." Referrals are now being accepted, and patients can schedule a consultation at About Reproductive Partners Medical Group With over 30 years of experience, Reproductive Partners Medical Group (RPMG) is known for delivering evidence-based fertility care. As part of the Ivy Fertility network, a globally respected leader in reproductive medicine, RPMG offers advanced treatments including IVF, IUI, third-party reproduction, and fertility preservation. The practice proudly serves all individuals and families, providing inclusive, expert care regardless of marital status, gender identity, or sexual orientation. About Ivy Fertility Ivy Fertility is globally recognized as pioneers and innovators in the field of advanced reproductive technologies, in-vitro fertilization, third-party reproduction, andrology, and fertility research. The Ivy Fertility network includes Dallas IVF, Fertility Associates of Memphis, Fertility Centers of Orange County, Idaho Fertility Center, IVF Fertility Center, Los Angeles Reproductive Center, Nevada Center for Reproductive Medicine, Nevada Fertility Center, Northern California Fertility Medical Center, NOVA IVF, Pacific Northwest Fertility, Reproductive Partners Medical Group, San Diego Fertility Center, Utah Fertility Center, and Virginia Fertility & IVF. By developing new procedures, achieving scientific breakthroughs, and teaching the latest techniques, Ivy Fertility upholds its commitment to successful outcomes and continually contributes to the development of the entire fertility community. The Ivy team is passionate about its family-building mission and works tirelessly each day to help patients become parents. View source version on Contacts Sara Zuboff, MBA, Marketing ManagerReproductive Partners Medical Groupszuboff@ | (310) 855-2229
